Mental health in the era of COVID-19: prevalence of psychiatric disorders in a cohort of patients with type 1 and type 2 diabetes during the social distancing

Janine Alessi1,2,8*, Giovana Berger de Oliveira3,9, Debora Wilke Franco3,9, Bibiana Brino do Amaral3,9, Alice Scalzilli Becker3,9, Carolina Padilla Knijnik3,9, Gabriel Luiz Kobe3,9, Taise Rosa de Carvalho3,9, Guilherme Heiden Telo4,9, Beatriz D. Schaan1,5,6,7,8 and Gabriela Heiden Telo2,3,4,7,9

Abstract

Background: In patients with diabetes, the prevalence of depression and anxiety symptoms is about two to four times greater than in the general population. The association between diabetes and mental health disorders could be exacerbated in a stressful environment, and psychological distress could increase depressive symptoms and cause adverse diabetes outcomes.

Objectives: To assess the prevalence of mental health disorders in patients with diabetes during the social distancing period due to COVID-19 pandemic.

Methods: This is a cross-sectional study developed to assess the impact of social distancing on a cohort of adults with type 1 (n = 52) and type 2 diabetes (n = 68) in Brazil. Inclusion criteria involved having an HbA1c test collected in the past 3 months and having a valid telephone number in electronic medical records. The primary outcome was the prevalence of minor psychiatric disorders, assessed by survey (SRQ-20). Secondary outcomes included the prevalence of diabetes related emotional distress, eating and sleeping disorders, all assessed by validated surveys at the moment of the study. Statistical analyses included unpaired t-test for continuous variables and χ2 test for categorical variables.

Results: Overall (n = 120), participants had a mean age of 54.8 ± 14.4 years-old, and HbA1c of 9.0 ± 1.6% (75 ± 17.5 mmol/mol); 93% of patients showed signs of current mental suffering based on the surveys measured. Almost 43% of patients showed evidence of significant psychological distress, with a significant greater tendency in patients with type 2 diabetes. The presence of diabetes related emotional distress was found in 29.2% of patients; eating disorders in 75.8%; and moderate/severe sleeping disorders in 77.5%.

Conclusions: We found a high prevalence of evidence of psychological distress among patients with diabetes during the COVID-19 pandemic and this highlights the need for mental health access and support for patients with type 1 and type 2 diabetes.

Keywords: Diabetes mellitus, Mental health, COVID-19 pandemic, Social distancing, Quarantine

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
presence of depression and anxiety symptoms may be associated with lower treatment adherence, leading to worse glycemic control [1, 2]. In patients with diabetes, the prevalence of depression and anxiety symptoms is about two to four times greater than in the general population [3, 4]. Although more research is needed to fully understand the link between diabetes and depression, it is clear that metabolic dysregulation influences brain function and disturbances in peripheral glucose regulation might be associated with depressed mood [5, 6]. Some cases of depression might result from low levels of insulin-like growth factor (IGF) into the brain, which was shown to produce antidepressant behavioural responses in experimental studies [6–8]. Nutrient-activated gut to brain signaling pathways also appear to play a role in the genesis of depressive symptoms. A highly significant association between leptin levels, depressed mood and sleep disturbances has been shown in normal-weight individuals [6, 9]. Also, ghrelin can exert antidepressant effects in men and carbohydrates appear to lead to ghrelin suppression [6, 10, 11].

The association between diabetes and mental health disorders could be exacerbated in a stressful environment, and psychological distress could increase depressive symptoms and cause adverse diabetes outcomes [12, 13]. The emergence of a potentially fatal pandemic represents a new reason for uncertainty and anxiety in this group of patients. Since December 2019, when a series of cases of severe pneumonia caused by a new coronavirus was described in Wuhan-China, the COVID-19 infection, as it became known, quickly spread throughout the world [14–16]. On Jul 07th, more than 11 million and 600 thousand confirmed cases have been identified worldwide, totaling 538 thousand deaths [17]. The first case of someone suffering from COVID-19 in South America was confirmed on February 26th, 2020 in São Paulo, Brazil. Since then, Brazil has recorded the largest number of cases in Latin America and recently has emerged as a new epicenter of the pandemic in the world [18].

A number of measures have been taken to prevent the spread of COVID-19, involving the isolation of suspected cases, tracking and monitoring of contacts, and dissemination of regional and national information, which included the recommendation of social distancing, especially for high risk groups such as patients with diabetes [19]. The social distancing recommendation have a psychological effect even in patients without diabetes, as shown by Talevi et al. [20]. In this review, the authors report that up to 53.8% of people experienced psychological distress during the initial stage of the COVID-19 outbreak. A range of negative psychological responses were identified, such as anxiety, depression, insomnia and worries about individuals’ own health and family. The levels of stress, anxiety and depression ranged from mild to moderate-severe [20–24]. Among patients with confirmed infection, findings show that nearly 50% of people diagnosed with COVID-19 had depressive symptoms, over 55% had anxiety and almost 70% had somatic symptoms [20, 25].

The psychological repercussion of the current scenario in patients with diabetes is still hypothetical. It is well known that those patients, due to the conditions of the underlying disease, already have a greater tendency to develop psychiatric disorders throughout life. It is possible that the COVID-19 pandemic, as well as the social isolation determined by it, may interfere with parameters of mental health in patients with diabetes. The present study aimed to investigate the impact of the current pandemic on the prevalence of mental health disorders in patients with type 1 and type 2 diabetes.

**Methods**

**Study design and setting**

This is a cross-sectional study developed to assess the prevalence of mental health disorders in a cohort of patients living with diabetes during the social distancing period due to COVID-19 pandemic. Electronic medical records were used to select patients with diabetes in a follow-up at the Endocrinology department of a public hospital in Southern Brazil. Patients who met the inclusion criteria received a telephone call for an invitation and application of the informed consent form (by electronic means or audio recording). Participants who agreed to participate in this study received a second phone call for data capture. All the study procedures started 1 month after the disclosure of the national ordinance that standardizes the social distancing recommendation for risk groups, including diabetes, in Brazil. At the time of the evaluation, the state of Rio Grande do Sul followed the Contingency Plan and State Action for the Prevention of the Human Infection COVID-19, which restricted the functioning of establishments that offer essential services and which regulated the indication of an exceptional teleworking regime for people with respiratory diseases, immunosuppressed or with chronic disease, upon medical recommendation. All data were collected in 8 days in order to have the same pandemic time for all participants. All contacts were made by telephone by trained researchers in order to preserve participants from social exposure. All data collected during the phone calls were recorded directly on an electronic database validated by the study staff.

**Participants**

Patients with type 1 and type 2 diabetes in a regular follow-up at the Endocrinology outpatient clinic, who
attended a medical appointment in a one-year period, for
type 2 diabetes, and three-year period for type 1 dia-
betes (from 2016 to 2019), were identified in an electronic
database. Inclusion criteria involved age ≥ 18 years old,
an hemoglobin A1c (HbA1c) test collected between
January and March 2020 at the hospital laboratory, and
having a valid telephone number in the electronic medi-
cal record. Patients who had any physical or cognitive
impairment that prevented the application of the study
questionnaires (such as dementia and severe hearing
impairment), as well as patients who were hospitalized at
the time of the study, were excluded.

Variables and data sources
The primary outcome assessed was the prevalence of
minor psychiatric disorders among patients with type 1
and type 2 diabetes. Secondary outcomes included the
prevalence of diabetes-related emotional distress, eating
disorders and sleeping disorders at the moment of the
study.

For the assessment of psychological distress, such as
anxiety and depression, the Brazilian validated version
of the Self Report Questionnaire-20 (SRQ 20) was used
[26, 27]. This 20-item questionnaire addresses questions
related to physical and psychoemotional symptoms
that may have been presented in the past 30 days, asking yes
or no questions. A positive screening for minor psychi-
atric disorders was considered when the survey scored
greater than or equal to 7, which was considered a sign of
current mental suffering.

Diabetes-related emotional distress was assessed by
the Brazilian validated version of the Problem Areas in
Diabetes Scale (B-PAID), which is a 20-item question-
aire that contemplates the patient’s perspective on the
impact of certain issues related to diabetes on a 4-point
response scale, with responses ranging from 0 = “it is not
a problem” to 4 = “it is a serious problem”. The scores for
each item were summed up, and then multiplied by 1.25
to generate a total score out of 100. Severe diabetes emo-
tional distress was considered present when the score
was greater than or equal to 40 [28, 29].

The prevalence of eating disorders was assessed by
the Brazilian validated version of the Eating Attitudes Test
(EAT-26). This survey addresses 26 issues related to eat-
ing habits and attitudes on a 3-point response scale, with
responses ranging from 0 = “never” to 3 = “always”. The
presence of a significant eating disorder was considered
when the score was greater than or equal to 20 [30, 31].

To assess sleep disorders, the Brazilian version of the
Mini Sleep Questionnaire (MSQ), a 10-item scale, was
used on a 7-point response scale, with responses rang-
ing from 1 = “never” to 7 = “always”. A sleep disorder
(moderate or severe) was considered when a score greater
than or equal to 28 was present [32, 33].

It should be noted that the scales used to assess men-
tal health disorders were designed for self-application.
The fact that those scales were applied by telephone
contact could be a potential source of bias. To minimize
this effect, the researchers strictly followed the steps of
the questionnaires, repeating the alternative answers to
each question only when requested to be as accurate as
possible.

Demographics and clinical data, such as the presence
of comorbidities, continuous use medications, weight
and height—obtained from the last visit for calculating
the body mass index (BMI) —, and HbA1c (high-perfor-
mance liquid chromatography method) data from the last
3 months were collected from electronic medical records.
Cardiovascular disease was considered present if there
was a previous history of coronary heart disease, stroke,
or heart failure registered in medical records. The pre-

cence of diabetes complications was also documented
according to medical records. The presence of retinopa-
thy was considered based on the last registered fundus
examination. For neuropathy, it was considered the pre-

cence of a documented diagnosis of previous neuropathy
or a monofilament 10 g test altered in the last medical
appointment. For diabetic nephropathy, it was consid-
ered the presence of microalbuminuria or chronic kidney
disease in which the etiology was attributed to diabetes in
the medical records.

Some clinical data, such as the use of antidepressant
or anxiolytic drugs and previous diagnosis of psychiatric
disorders, were obtained from both electronic medical
records and checked directly with the patients during the
phone calls. Previous diagnosis of common mental dis-
order was considered if there was a previous or current
diagnosis of depressive episode, major depressive disor-
der or anxiety disorders. Compliance with the recom-
mandation of social distance was questioned directly to
the participants according to the follow: (1) total social
distancing was considered when the patient did not leave
the house under any circumstances; (2) partial social dis-
tancing was considered when the patient left the house
only for basic activities (such as going to the market and
pharmacy); or (3) no social distancing, when the patient
maintained regular activities.

The institutional ethics committee approved the study
protocol (Number 4.029.368), and all authors signed the
confidentiality document for data use.

Sample size
The sample size was calculated for a prevalence survey
with finite population correction. Considering that the
prevalence of anxiety and depression disorders among
patients with type 1 was 17.6% and type 2 diabetes was 16%, we considered a mean prevalence known of 17%. The calculation was performed taking into account that in 2019 there were 16.8 million individuals with diabetes in Brazil. The number required for an analysis with 5% accuracy and 85% confidence level was 117 patients [4, 34, 35]. The number of patients included with type 1 diabetes and type 2 diabetes was determined randomly. The limitations imposed by the current pandemic and the recommendation of social distancing to patients with diabetes added difficulty in approaching and contacting a greater number of patients, which motivated the choice of the 85% confidence level.

Statistical methods
Analyses were performed using SPSS Statistics 20. Descriptive data are presented as mean and standard deviation (SD) or percentages. The data distribution was analysed and, since it had a normal distribution, parametric tests were used. In order to evaluate possible differences according to diabetes type, statistical analyses included unpaired \( t \)-test for continuous variables and \( \chi^2 \) test for categorical variables. The primary outcome (minor psychiatric disorders) was then evaluated as the dependent variable in a multivariable logistic regression model designed to control for possible confounders in the interaction between the primary outcome and the diabetes type. An \( \alpha \) level of \( \leq 0.05 \) was used to determine statistical significance. This study followed the STROBE statement for the reporting.

Results
Participant characteristics
A total of 245 potentially eligible patients were identified, and 146 were randomly recruited to participate in the study. The recruitment stopped after inclusion of the planned sample size, when 120 individuals, 52 with type 1 and 68 with type 2 diabetes, agreed to participate and provided informed consent (see Additional file 1: Figure S1). Age, sex, diabetes duration, and HbA1c levels did not differ by enrollment status (data not shown).

Overall (\( n = 120 \)), participants had a mean age of 54.8 ± 14.4 years old; 55.8% were female, 85.8% white and 76.7% overweight/obese. The mean diabetes duration was 21.8 ± 10.9 years and the HbA1c value was 9.0 ± 1.6% (75 ± 17.5 mmol/mol) (see Table 1). Patients with type 2 diabetes were older (62.3 ± 9.1 vs. 45.0 ± 14.2 years of age; \( p < 0.001 \)), had a greater racial representation (22.1% vs. 3.8% not white; \( p = 0.02 \)) and a higher prevalence of overweight and obesity (95.6% vs. 51.9%; \( p < 0.001 \)), when compared with patients with type 1 diabetes. Although younger, type 1 diabetes patients had a longer diabetes duration (25.2 ± 11.5 vs.

| Table 1 Demographics and clinical characteristics of study participants |
|------------------------|-------------------|-------------------|--------|
|                       | Total (\( n = 120 \)) | Type 1 diabetes (\( n = 53 \)) | Type 2 diabetes (\( n = 68 \)) | \( P \) value |
| Age (years)            | 54.8 ± 14.4        | 45.0 ± 14.2        | 62.3 ± 9.1        | <0.001      |
| Sex (% female)         | 55.8%              | 48.1%              | 61.8%             | 0.13        |
| Race/ethnicity (% white) | 85.8%            | 96.2%              | 77.9%             | 0.02        |
| Diabetes duration (years) | 21.8 ± 10.9     | 25.2 ± 11.5        | 19.2 ± 9.7        | <0.001      |
| Age at diabetes diagnosis (years) | 32.7 ± 16.1 | 19.8 ± 12.7        | 42.8 ± 10.3       | <0.001      |
| HbA1c (%) (mmol/mol)   | 9.0 ± 1.6          | 8.8 ± 1.5          | 9.1 ± 1.7         | 0.29        |
| BMI (% overweight/obese) | 76.7%             | 51.9%              | 95.6%             | <0.001      |
| Systemic arterial hypertension (%) | 58.3%     | 30.8%              | 79.4%             | <0.001      |
| Cardiovascular disease  | 29.2%              | 15.4%              | 39.7%             | <0.001      |
| ACE inhibitors use     | 46.7%              | 30.8%              | 58.8%             | <0.001      |
| Previous diagnosis of common mental disorders* | 23.3%    | 25.0%              | 22.1%             | 0.70        |
| Social distancing (% total/partial) | 92.5%  | 88.5%              | 95.6%             | 0.14        |

Data are mean ± standard deviation or %. An \( \alpha \) level of \( \leq 0.05 \) indicates significant difference. BMI, Body mass index; HbA1c, hemoglobin A1c. ACE, Angiotensin-converting enzyme; * Common mental disorders, which includes depressive episode, major depressive disorder and anxiety disorders. ** Social distancing includes patients who followed the orientation of total (home-staying only) or partial social isolation (left home only for basic activities, such as market, pharmacy and health care)
19.2 ± 9.7 years; \( p < 0.01 \). Both groups were comparable with respect to HbA1c levels and presence of diabetes complications.

From the whole group, 9 patients (7 type 1, and 3 type 2 diabetes) had some previous serious psychiatric diagnosis, which were not considered as common mental disorders in analysis. Among patients with type 1 diabetes, 3 had a diagnosis of schizophrenia; 1 bipolar mood disorder; 1 borderline personality disorder; and 1 self-mutilation history. Among patients with type 2 diabetes, 1 patient had a previous diagnosis of schizophrenia and 1 had a diagnosis of obsessive–compulsive disorder. There was no difference between type 1 and type 2 diabetes regarding the presence of previous common mental disorders. Regarding social distancing, in total, 42.5% of patients were following the guidance of total isolation, 50% were on partial social distancing (leaving home only for basic activities) and only 7.5% were not on doing any type of social distancing (keeping regular daily activities). There was no difference between groups with regard to social distancing.

Survey results

In the studied participants, 93.3% (94.2% in type 1 and 92.6% in type 2 diabetes, \( p = 0.73 \)) had some sign of a psychiatric disorder, which was assessed by a positive screening in at least one of all the specific scales measured in this study (minor psychiatric disorders, diabetes-related emotional distress, and eating and sleeping disorders).

Regarding the primary outcome, the presence of psychological distress, that measure depressive and anxiety symptoms, 44.2% of patients had a positive screening based on the SRQ 20 (see Fig. 1). In the type 1 diabetes group, this prevalence was 32.7%, while in the group with type 2 diabetes, the prevalence of psychological distress was higher, 52.9% \( (p = 0.03) \). The question number 17 of the SRQ 20 (“has the thought of ending your life been on your mind”) addresses suicidal ideation, and, overall, 6.7% of patients had a positive response to this item. Also, considering all the demographic and clinical differences between type 1 and type 2 diabetes patients showed in Table 1, we performed a multivariable logistic regression to evaluate the impact of variables of clinical
interest on the interaction between the primary outcome (minor psychiatric disorders) and the type of diabetes (see Table 2). We included into the model: age, sex, race/ethnicity, age of diabetes diagnosis, HbA1c, BMI, previous common mental disorders, and social distancing. The adjusted Odds Ratio and its 95% confidence interval for the interaction between minor psychiatric disorders and type 2 diabetes was 7.60 (1.97–29.34).

Secondary outcomes included the prevalence of diabetes-related emotional distress, eating disorders and sleeping disorders. The presence of diabetes-related emotional distress was found in 29.2% of patients; eating disorders in 75.8%; and moderate/severe sleeping disorders in 77.5% of patients (Fig. 1). There was no significant difference in these outcomes between patients with type 1 and type 2 diabetes. In the type 1 diabetes group, the prevalence of diabetes-related emotional distress was 28.8% vs. 29.4% in the type 2 diabetes group (p = 0.95). For the eating disorders evaluation, 78.8% of patients with type 1 diabetes showed a positive screening for eating disorders vs. 73.5% of those living with type 2 diabetes (p = 0.50). In the analysis of sleep pattern, 76.9% of patients with type 1 diabetes showed signs of moderate/severe sleep disorder vs. 77.9% of those living with type 2 diabetes (p = 0.89). We also performed a multivariable logistic regression to evaluate the impact of BMI on the interaction between the positive screening for eating and sleeping disorders and the type of diabetes, and no significant interaction was identified (data not shown).

### Discussion and conclusions

In this study, we sought to investigate psychological characteristics of people living with diabetes after 1 month of social distancing recommendations in Brazil. We found a high prevalence of significant psychological distress among patients with type 1 and type 2 diabetes, with approximately 93% of the studied patients showing signs of current mental suffering in some psychological specific area. Almost half of the patients had a positive screening for psychological distress, such as anxiety and depression, with a significantly greater tendency in patients with type 2 diabetes. The presence of diabetes-related emotional distress was present in only 29.2% of the interviewees, which does not appear to directly justify the high prevalence of psychiatric disorders found in this study. Approximately three out of four patients had a positive screening for eating and sleeping disorders, which may reflect the systemic repercussion of a latent anxiety condition.

It is well documented that depression and anxiety are more prevalent among patients with diabetes when compared to general population [36–38]. An epidemiological study by Meurs et al. evaluating more than 90,000 patients found an 80% increased risk of depression and anxiety in patients with diabetes [36]. The data described in the literature shows a co-prevalence of diabetes and depression ranging from 17.6 to 21% [39, 40]. In Brazil, the prevalence of depression in patients with diabetes, in usual situations, appears to be similar to that found in other countries, reaching 22% in the most recently published study [41]. Considering the current scenario, a study by Huang et al. in China showed a prevalence of anxiety and depression in the general population of 35% and 20%, respectively [42]. This makes us reflect about the possible impact that 1 month of social distancing, associated with all the stressors related to the current pandemic, has on this group of patients. Health appointments not fully available, difficulties in obtaining diabetes medications and supplies, besides the lack of scientific information regarding the real relationship between COVID-19 and diabetes, may have contributed to the high prevalence of psychological distress found in patients who followed the orientation of total or partial social detachment (left home only for basic activities, such as market, pharmacy and health care).

### Table 2 Multivariable logistic regression to identify predictors of minor psychiatric disorders

| Predictor                                      | Odds ratio | Confidence interval (95%) | P value |
|------------------------------------------------|------------|---------------------------|---------|
| Age at diagnosis (per 1 year increase)         | 0.96       | 0.92–0.99                 | 0.04    |
| Sex (female)                                   | 2.24       | 0.95–5.32                 | 0.06    |
| BMI (eutrophic)                                | 1.77       | 0.56–5.56                 | 0.33    |
| Age (per 1 year increase)                      | 1.01       | 0.97–1.06                 | 0.66    |
| Previous diagnosis of common mental disorders  | 1.15       | 0.43–3.11                 | 0.77    |
| HbA1c (per 1% increase)                        | 1.03       | 0.79–1.35                 | 0.81    |
| Race/ethnicity (white)                         | 1.01       | 0.28–3.64                 | 0.98    |
| Social distancing                              | 2.04       | 0.35–11.81                | 0.42    |
| Type 2 diabetes                                | 7.60       | 1.93–29.71                | 0.004   |

Multivariable logistic regression model to assess predictors of the presence of minor psychiatric disorders ($\chi^2 = 17.94, p < 0.05, R^2$ Nagelkerke 0.19). BMI, Body mass index; HbA1c, hemoglobin A1c. Common mental disorders includes depressive episode, major depressive disorder and anxiety disorders. Social distancing includes patients who followed the orientation of total or partial social detachment (left home only for basic activities, such as market, pharmacy and health care).
this study. The possible vulnerability intrinsic to diabetes seems to be exacerbated in the current scenario.

It is important to notice that the COVID-19 pandemic may impact patients with type 1 and type 2 diabetes differently. There is a tendency for a higher prevalence of depression in patients with type 2 diabetes when compared to those with type 1 diabetes in normal situations. A study performed by Bak et al. showed that patients with type 2 diabetes had almost twice the prevalence of depression symptoms when compared to those with type 1 diabetes [43]. In addition, intrinsic differences in types of diabetes can be affected in different ways during the period of social distancing. In type 1 diabetes, which requires precision in terms of the amount and timing of insulin administration, having more time at home could result in improved adherence and disease control. On the other hand, in type 2 diabetes, the maintenance of healthy habits, including physical exercise and balanced diet, can be greatly impaired during quarantine. These possible differences can have a positive or negative impact in terms of glycemic control, contributing differently to the appearance of psychological distress during the COVID-19 pandemic. It should be noted that these differences are still hypothetical, requiring specific studies for a better understanding.

Besides the high prevalence of psychological distress, our findings highlight the observation that the risk of suicide may be increased during the period of social distancing by COVID-19 in patients with diabetes. In the studied cohort, almost 7% of patients expressed positive responses to the question “has the thought of ending your life been on your mind?” in the SRQ 20. It is important to notice that the questionnaires were applied in a single phone call interview generated by researchers who had no bond or previous connection with participants. It is possible that, if applied under other conditions, this number would be even higher. Our findings are compatible with what was exposed by Gunnel et al., which stated that the pandemic would cause distress and leave many people vulnerable to mental health problems and suicidal behavior. Mental health consequences are likely to be present for longer and peak later than the actual pandemic [44]. This reinforces the importance of the active and ongoing participation of mental health professionals in policy task forces during this critical period [45].

Our study also showed a high prevalence of eating disorders among patients with diabetes after 1 month of social distancing. Literature data show that approximately 14% to 35% of patients with diabetes have a positive screening for eating disorders when assessed by EAT-26, a percentage much lower than the one found in our cohort [46, 47]. A pilot study by Fernandez-Aranda et al. demonstrated that, after just 2 weeks of confinement, almost 38% of patients reported symptoms related to eating disorders. The authors reflect that concerns about health and fitness during confinement might serve as a precipitating factor for the development of an eating disorder in vulnerable individuals [48]. It is important to note that our study was carried out after a longer period of social distancing, but in milder confinement conditions, different from the lockdown measures evaluated in the study by Fernandez-Aranda et al. Nevertheless, although not evaluated in our study, the high prevalence of eating disorders in this population could interfere in diet and, consequently, in glycemic control.

Another relevant aspect of our study was the high prevalence of sleep disorders in patients with diabetes during this period. Only one study was carried out to assess sleep quality during the COVID-19 pandemic, which showed 18% prevalence of sleeping disorders [43]. We believe that the presence of a positive screening for moderate and severe sleep disorder in our cohort is possibly multifactorial: the presence of obstructive sleep apnea in the groups with highest BMI, eventual nocturnal hypoglycemia episodes, staying longer time at home, practicing less physical activity, and having irregular sleep times may play an important role in this variable. In addition, it is possible that the presence of insomnia in this period reflects an anxiety sign related to a heightened concern about the risk of having COVID-19 while having diabetes. These hypotheses are merely speculation, requiring specific studies for better understanding.

It is important to highlight some limitations of the present study. This study involved a cross-sectional research design and data regarding mental health that was not assessed before the period of social distancing for comparison in this same population. The absence of a control group without diabetes is also a limitation of the study. It must be taken into account that a relatively small sample was included in this study, although in accordance to the sample size calculation. In addition, patients were selected from a single tertiary center, which can limit external validity. Some parameters, such as labor activities and patients’ current purchasing power, and specific information on the use of antipsychotics and mood stabilizers were not available in the electronic medical records and were not assessed directly with the participants, not allowing us to interpret the medication use and economic impact of this period in mental health.

Some limitations should be considered in relation to the scales used. The scales used to assess psychiatric disorders work as screening tools and have no diagnostic value. The scales used were originally validated for self-application and, in our study, they were applied by researchers through phone calls due to the limitations imposed by the current scenario. The
self-report-questionnaire (SRQ-20), which was used to assess the primary outcome, has validation for minor psychiatric disorders screening in primary health care in Brazil [48]. Despite not presenting validation for screening in patients in tertiary care, patients with diabetes mellitus are included in primary care samples. For the assessment of eating disorders, the eating attitudes test (EAT-26) was used. Although there are no validation studies in the population with diabetes, their results are widely generalizable and used for screening, indicating food preoccupation and restriction [30, 31]. The EAT-26 is often indicated as one of the methods of choice for the initial assessment of eating disorders in patients with diabetes, according to Young-Hyman et al. [49]. The mini sleep questionnaire (MSQ) used to assess sleep disorders has validation only for the general population and there are no specific studies on its use in patients with diabetes [32, 33].

Despite not having a diagnostic purpose, this study found a high number of patients showing evidence of significant psychological distress among patients with type 1 and type 2 diabetes during the COVID-19 pandemic. Our results serve as an alarm for the impact that the current scenario may have on the mental health of patients with diabetes. The data from this study highlight the need for mental health access and support for patients with type 1 and type 2 diabetes during and after this pandemic. Future studies and actions should address the impact of strategies to care for mental health in diabetes and to prevent glycemic control deterioration during a quarantine period.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13098-020-00584-6.

Acknowledgements
This work was conducted with support from Hospital de Clínicas de Porto Alegre, Programa de Pós Graduação em Ciências Médicas em Endocrinologia da Universidade Federal do Rio Grande do Sul, Faculdade de Medicina da Pontifícia Universidade Católica do Rio Grande do Sul and Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, and National Institute of Science and Technology for Health Technology Assessment (IATS) – CNPq, Brazil (project: 465518/2014-1).

Authors’ contributions
JA conceptualization, methodology, software, data curation, writing—original draft preparation. GBO, DWF, GLK, ASB, BA, CPK, TRC and GHT methodology, investigation. GHT methodology, investigation. BDS conceptualization, validation, supervision, writing—reviewing and editing. GHT conceptualization, data curation, writing—original draft preparation. Supervision. JA is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Funding
This work was supported by FIPE (Fundo de Incentivo à Pesquisa e Eventos) of Hospital de Clínicas de Porto Alegre, and Programa de Pós Graduação em Ciências Médicas em Endocrinologia da Universidade Federal do Rio Grande do Sul. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The data collected for the study, including deidentified participant data and informed consent form, will be available for 1 year after publication of the article upon justified request to the e-mail address of the main researcher and with a signed data access agreement.

Ethics approval and consent to participate
The study was approved by the National Research Ethics Commission of Brazil (CONEP), number 4.029.368. All participants agreed to the free and informed consent form, which was saved by electronic registration.

Consent for publication
All authors have reviewed the final version of the manuscript and agree with the publication of the results presented.

Competing interests
There is no conflict of interest to declare.

Author details
1 Post-Graduate Program in Medical Science: Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 2 Internal Medicine Department, Hospital São Lucas-Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 3 School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 4 Post-Graduate Program in Medicine and Health Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 5 School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 6 Endocrinology division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 7 National Institute of Science and Technology for Health Technology Assessment (IATS) – CNPq, Porto Alegre, Brazil. 8 Hospital de Clínicas de Porto Alegre, HC-Pa, Porto Alegre, Rio Grande do Sul, Brazil. 9 Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande do Sul, Brazil.

Received: 9 July 2020 Accepted: 18 August 2020
Published online: 31 August 2020

References
1. Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol. 2015;3,4:53–60.
2. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, Safren SA. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:2398–403.
3. Buchberger B, Huppertz H, Krabbe L, Lux B, Mattivi JT, Siafarikas A. Symptoms of depression and anxiety in youth with type 1 diabetes: a systematic review and meta-analysis. Psychoneuroendocrinology. 2016;70:70–84.
4. Semenovich K, Brown ME, Srivatic DM, Lustman PJ. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs. 2015;75,577–87.
5. Hendrick C, McEwen BS, Ouderaa F. Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol Aging. 2005;26:1–5.
6. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31(6):761–77. https://doi.org/10.1159/000350094.
7. Hoshav BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037:204–8.
8. Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rozenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF
binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007;32:2360–8.

9. Hafner S, Baumert J, Emery RT, Lacroz ME, Thorand B, Herder C, Koenig W, Rupprecht R, Ladwig KH. Sleep disturbances and depressed mood: a harmful combination associated with increased leptin levels in women with normal weight. Biol Psychol. 2012;89:163–9.

10. Kluge M, Schüssler P, Dresler M, Schmidt D, Yassouridis A, Uhr M, Steiger A. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J Psychiatr Res. 2011;45:421–6.

11. Kokalé C, Kokoïnos A, Tontolouris N, Katsilambros N. The effect of ingested macronutrients on postprandial ghrelin response: a critical review of existing literature data. Int J Pept. 2010. https://doi.org/10.1155/2011/701852.

12. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912–20.

13. Mukhtar S. Mental health and psychological distress in people with diabetes during COVID-19. Metabolism: 2020;108:152448.

14. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, Team CNCoRa. A novel coronavirus from patients with pneumonia in China. 2019. N Engl J Med. 2020;382:727–33.

15. Centers for Disease Control and Prevention (CDC). People who are at higher risk for severe illness. Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html#COVID-19-fact-sheet-ncov-revised-1c93dcdceef9_2. Accessed 4 May 2020.

16.后备文献：https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html#COVID-19-fact-sheet-ncov-revised-1c93dcdceef9_2. Accessed 4 May 2020.

17. World Health Organization (WHO). COVID-19 situation reports. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-streetep-39-coronavirus.pdf?sfvrsn=c3dcdceef9_2. Accessed 4 May 2020.

18. Candido DDS, Watts A, Abade L, Kraemer MU, Yúctug B, Ogb, Croda J, Oliveira W, Khan K, Sabino EC, Faria NR. Routes for COVID-19 importation in Brazil. J Travel Med. 2020;27(3):taaa042. https://doi.org/10.1093/jtm/taaa042.

19. Centers for Disease Control and Prevention (CDC). People who are at higher risk for severe illness. Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html#COVID-19-fact-sheet-ncov-revised-1c93dcdceef9_2. Accessed 4 May 2020.

20. Centers for Disease Control and Prevention (CDC). People who are at higher risk for severe illness. Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html#COVID-19-fact-sheet-ncov-revised-1c93dcdceef9_2. Accessed 4 May 2020.

21. Li S, Wang Y, Xue J, Zhao N, Zhu T. The impact of COVID-19 epidemic declaration on psychological consequences: a study on active weibo users. Int J Environ Res Public Health. 2020;17:E2032.

22. Liu N, Zhang F, Wei C, et al. Prevalence and predictors of PTSS during the COVID-19 pandemic. Psychol Health Med. 2020;25:421–6.

23. Falavigna A, de Souza Bezerra ML, Teles AR, Kleber FD, Velho MC, da Silva RC, Mazzochin T, Santin JT, Mosena G, de Braga GL, Petry FL, de Lessa Medina MF. Consistency and reliability of the Brazilian Portuguese version of the Mini-Sleep Questionnaire in undergraduate students. Sleep Breath. 2011;15:351–5.

24. Zomer J, Peled R, Rubin A, Lavi P. Mini-Sleep Questionnaire (MSQ) for screening large populations for EDS complaints. In: Koella WP; Ruther; Schulz H (editors): Proceedings of the Seventh European Congress on Sleep – Research. Fischer, Stuttgart. Sleep. 1985;84:467–470.

25. World Health Organization (WHO). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization. 2017. Licence: CC BY-NC-SA 2.0 IGO.

26. Melzak B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383–90.

27. Smith RJ, Blandard L, Mother E, Ganev P, Page V, Badawi G, Rabasa-Lhoret R, Schmidt N. Association of diabetes with anxiety: a systematic review and meta-analysis. J Psychosom Res. 2013;74:89–99.

28. Anderson RJ, Blandand L, Mother E, Ganev P, Page V, Badawi G, Rabasa-Lhoret R, Schmidt N. Association of diabetes with anxiety: a systematic review and meta-analysis. J Psychosom Res. 2013;74:89–99.

29. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.

30. Falavigna A, de Souza Bezerra ML, Teles AR, Kleber FD, Velho MC, da Silva RC, Mazzochin T, Santin JT, Mosena G, de Braga GL, Petry FL, de Lessa Medina MF. Consistency and reliability of the Brazilian Portuguese version of the Mini-Sleep Questionnaire in undergraduate students. Sleep Breath. 2011;15:351–5.

31. Bak E, Marcisz-Dyla E, Mlynarska A, Sternal D, Kadlubowska M, Marcisz C. Association between diabetes mellitus and depressive symptoms in the Brazilian population. Rev Saúde Pública. 2019;53:1–10.

32. Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional survey. Psychiatry Res. 2020;288:1129–54.

33. Gudin J, Simó R, Sanchís P, Ayala L, Fortuny R, Zubillaga I, Masmiquel L. Eating disorders are frequent among type 2 diabetic patients and are associated with worse metabolic and psychological outcomes: results from a cross-sectional study in primary and secondary care settings. Acta Diabetol. 2015;52:1037–44.

34. Falavigna A, de Souza Bezerra ML, Teles AR, Kleber FD, Velho MC, da Silva RC, Mazzochin T, Santin JT, Mosena G, de Braga GL, Petry FL, de Lessa Medina MF. Consistency and reliability of the Brazilian Portuguese version of the Mini-Sleep Questionnaire in undergraduate students. Sleep Breath. 2011;15:351–5.

35. Garner DM. Garfinkel PE. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. Psychol Med. 1979;9(2):2739.

36. Falavigna A, de Souza Bezerra ML, Teles AR, Kleber FD, Velho MC, da Silva RC, Mazzochin T, Santin JT, Mosena G, de Braga GL, Petry FL, de Lessa Medina MF. Consistency and reliability of the Brazilian Portuguese version of the Mini-Sleep Questionnaire in undergraduate students. Sleep Breath. 2011;15:351–5.

37. Dudley DM, Bakish DM, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383–90.

38. Smith RJ, Blandand L, Mother E, Ganev P, Page V, Badawi G, Rabasa-Lhoret R, Schmidt N. Association of diabetes with anxiety: a systematic review and meta-analysis. J Psychosom Res. 2013;74:89–99.

39. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of co-morbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.

40. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–73.

41. Briegant CP, Silva MT, de Almeida JV, Bergamaschi CC. Association between diabetes mellitus and depressive symptoms in the Brazilian population. Rev Saúde Pública. 2019;53:1–10.

42. Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional survey. Psychiatry Res. 2020;288:1129–54.

43. Bak E, Marcisz-Dyla E, Mlynarska A, Sternal D, Kadlubowska M, Marcisz C. Prevalence of depressive symptoms in patients with type 1 and 2 diabetes mellitus. Patient Prefer Adherence. 2020;14:443–54.

44. Gunnell D, Appleby L, Anensman E, Hawton K, John A, Kapur N, Khan M, O’Connor RC, Pirkis J, Collaboration C-SPR. Suicide risk and prevention during the COVID-19 pandemic. Lancet Psychiatry. 2020. https://doi.org/10.1016/S2215-0366(20)30171-1.

45. Sani G, Janiri D, Di Nicola M, Janiri L, Ferrer S, Chieffo D. Mental health during and after the COVID-19 emergency in Italy. Psychiatry Clin Neurosci. 2020;74(6):372.
Tchanturia K, Treasure J. COVID-19 and implications for eating disorders. Eur Eat Disord Rev. 2020;28:239–45.

49. Mari JJ, Williams P. A validity study of a psychiatric screening questionnaire (SRQ-20) in primary care in the city of São Paulo. Br J Psychiatry. 1986;148:23–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.